Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FO2CUS: Vadadustat vs Mircera for Anemia in Hemodialysis
NCT04707768Phase 3Completed
- Sponsor
- Akebia Therapeutics
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Akebia Therapeutics. Primary endpoint: Change From Baseline in Hemoglobin to the Average Over the Primary Evaluation Period. Started Jun 2021; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04707768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707768.